Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: Discovery and preliminary SAR of benzimidazole derivatives

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 1, 2004, Pages 119-124

  Beaulieu, Pierre L ^a   Bös, Michael ^a   Bousquet, Yves ^a   Fazal, Gulrez ^a   Gauthier, Jean ^a   Gillard, James ^a   Goulet, Sylvie ^a   LaPlante, Steven ^a   Poupart, Marc André ^a   Lefebvre, Sylvain ^a   McKercher, Ginette ^a   Pellerin, Charles ^a   Austel, Volkhard ^b   Kukolj, George ^a  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAZOLE 5 CARBOXAMIDE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; ENZYME INHIBITOR; NON STRUCTURAL 5B POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS ENZYME;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HEPATITIS C VIRUS; NONHUMAN; SCREENING; STRUCTURE ACTIVITY RELATION;

HEPATITIS C VIRUS;

EID: 0348143476     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.10.023     Document Type: Article

References (20)

1. Choo Q.-L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Science. 244:1989;359.
2. Wasley A., Alter M.J. Semin. Liver Dis. 20:2000;1.
3. Berenger M., Wright T.L. Proc. Assoc. Am. Phys. 110:1998;98.
4. Di Bisceglie A.M., Hoofnagle J.H. Hepatology. 36(Suppl. 1):2002;S121.
5. (a) Beaulieu P.L., Llinàs-Brunet M. Curr. Med. Chem. Anti-Infective Agents. 1:2002;163.
6. (b) For recent disclosures of other non-nucleoside HCV NS5B polymerase inhibitors, see: Dhanak D., Duffy K.J., Johnston V.K., Lin-Goerke J., Darcy M., Shaw A.N., Gu B., Silverman C., Gates A.T., Nonnemacher M.R., Earnshaw D.L., Casper D.J., Kaura A., Baker A., Greenwood C., Gutshall L.L., Maley D., DelVecchio A., Macarron R., Hofmann G.A., Alnoah Z., Cheng H.-Y., Chan G., Khandekar S., Keenan R.M., Sarisky R.T. J. Biol. Chem. 277:2002;38322 (c) Chan L., Reddy T.J., Proulx M., Das S.K., Pereira O., Wang W., Siddiqui A., Yannopoulos C.G., Poisson C., Turcotte N., Drouin A., Alaoui-Ismaili M.H., Bethell R., Hamel M., L'Heureux L., Bilimoria D., Nguyen-Ba N. J. Med. Chem. 46:2003;1283.
7. (b) For recent disclosures of other non-nucleoside HCV NS5B polymerase inhibitors, see: Dhanak D., Duffy K.J., Johnston V.K., Lin-Goerke J., Darcy M., Shaw A.N., Gu B., Silverman C., Gates A.T., Nonnemacher M.R., Earnshaw D.L., Casper D.J., Kaura A., Baker A., Greenwood C., Gutshall L.L., Maley D., DelVecchio A., Macarron R., Hofmann G.A., Alnoah Z., Cheng H.-Y., Chan G., Khandekar S., Keenan R.M., Sarisky R.T. J. Biol. Chem. 277:2002;38322 (c) Chan L., Reddy T.J., Proulx M., Das S.K., Pereira O., Wang W., Siddiqui A., Yannopoulos C.G., Poisson C., Turcotte N., Drouin A., Alaoui-Ismaili M.H., Bethell R., Hamel M., L'Heureux L., Bilimoria D., Nguyen-Ba N. J. Med. Chem. 46:2003;1283.
8. Reed K.E., Rice C.M. Curr. Top. Microbiol. Immunol. 242:2000;55.
9. Kolykhalov A.A., Mihalik K., Feinstone S.M., Rice C.M. J. Virol. 74:2000;2046.
10. (a) Behrens S.-E., Tomei L., De Francesco R. EMBO J. 15:1996;12.
11. (b) Lohmann V., Körner F., Herian H., Bartenschlager R. J. Virol. 71:1997;8416.
12. 11a A more detailed description of this assay will be published else where (McKercher, G. et al.).
13. 9,11a.
14. (a) Austel, V., Beaulieu, P. L., Fazal, G., Gillard, J., Kukolj, G. US patents 6,448,281 B1 and 6,479,508 B1, 2002, to Boehringer Ingelheim (Canada) Ltd.
15. (b) A recent patent application from Japan Tobacco Inc. also discloses derivatives of benzimidazole 5-carboxylic acids as HCV polymerase inhibitors: Hashimoto, H., Mizutani, K., Yishida, A. EP 1 162 196 A1, 2001.
16. 2O (v/v). Data acquisition was performed at 600 MHz and 300 K using methods similar to those reported previously: LaPlante, S. R.; Cameron, D. R.; Aubry, N.; LeFebvre, S.; Kukolj, G.; Maurice, R.; Thibeault, D.; Lamarre, D.; Llinas-Brunet, M. J. Biol. Chem. 1999, 274, 18618. A soluble form of the polymerase, NS5BΔ21, lacking C-terminal 21 amino acids was used: Ferrari, E.; Wright-Minogue, J.; Fang, J. W. S.; Baroudy, B. M.; Lau, J. Y. N.; Hong, Z. J. Virol. 1999, 73, 1649.
17. Lohmann V., Körner F., Koch J.O., Herian U., Theilmann L., Bartenschlager R. Science. 285:1999;110.
18. (a) Grimmet, M. R.; In Comprehensive Heterocyclic Chemistry; Katritzky, A. R., Rees, C. W., Eds.; Pergamon: Oxford, 1984; Vol. 5, p 457.
19. (b) Mayer J.P., Lewis G.S., McGee C., Bankaitis-Davis D. Tetrahedron Lett. 39:1998;6655.
20. (c) For the use of oxone® in the synthesis of benzimidazoles from aldehydes and 1,2-phenylenediamines see: Beaulieu P.L., Haché B., von Moos E. Synthesis. 2003;1683.